Stock Analysis on Net

Intuitive Surgical Inc. (NASDAQ:ISRG)

Income Statement 
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Intuitive Surgical Inc., consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Product 2,048,800 1,890,400 2,066,100 1,709,200 1,692,600 1,577,100 1,623,900 1,450,800 1,468,600 1,413,000 1,391,700 1,297,500 1,270,400 1,238,400 1,312,700 1,170,600 1,236,000 1,074,600 1,113,600 898,400 721,800 900,800
Service 391,200 363,000 347,400 328,900 317,300 313,500 304,400 292,900 287,300 283,200 263,300 259,900 251,700 249,300 238,000 232,700 228,000 217,500 215,500 179,300 130,300 198,700
Revenue 2,440,000 2,253,400 2,413,500 2,038,100 2,009,900 1,890,600 1,928,300 1,743,700 1,755,900 1,696,200 1,655,000 1,557,400 1,522,100 1,487,700 1,550,700 1,403,300 1,464,000 1,292,100 1,329,100 1,077,700 852,100 1,099,500
Product (686,200) (670,700) (663,900) (555,400) (539,400) (554,400) (561,300) (489,500) (498,000) (493,000) (460,400) (421,600) (421,000) (397,300) (415,000) (355,800) (374,000) (319,300) (362,100) (287,700) (283,800) (296,700)
Service (135,900) (125,000) (107,400) (108,800) (97,800) (90,800) (89,600) (87,000) (86,000) (90,200) (83,700) (83,700) (77,800) (80,700) (74,900) (76,100) (66,300) (70,200) (71,200) (65,700) (65,400) (64,600)
Cost of revenue (822,100) (795,700) (771,300) (664,200) (637,200) (645,200) (650,900) (576,500) (584,000) (583,200) (544,100) (505,300) (498,800) (478,000) (489,900) (431,900) (440,300) (389,500) (433,300) (353,400) (349,200) (361,300)
Gross profit 1,617,900 1,457,700 1,642,200 1,373,900 1,372,700 1,245,400 1,277,400 1,167,200 1,171,900 1,113,000 1,110,900 1,052,100 1,023,300 1,009,700 1,060,800 971,400 1,023,700 902,600 895,800 724,300 502,900 738,200
Selling, general and administrative (561,200) (563,400) (612,600) (510,600) (525,300) (491,500) (567,100) (452,000) (464,300) (480,500) (494,300) (436,100) (418,400) (391,100) (427,000) (363,300) (350,200) (326,000) (330,200) (298,900) (279,100) (308,100)
Research and development (313,300) (316,200) (294,700) (286,000) (280,100) (284,500) (260,100) (249,400) (244,400) (244,900) (244,100) (217,100) (207,300) (210,500) (183,400) (165,500) (162,300) (159,800) (149,800) (155,000) (143,200) (147,100)
Operating expenses (874,500) (879,600) (907,300) (796,600) (805,400) (776,000) (827,200) (701,400) (708,700) (725,400) (738,400) (653,200) (625,700) (601,600) (610,400) (528,800) (512,500) (485,800) (480,000) (453,900) (422,300) (455,200)
Income from operations 743,400 578,100 734,900 577,300 567,300 469,400 450,200 465,800 463,200 387,600 372,500 398,900 397,600 408,100 450,400 442,600 511,200 416,800 415,800 270,400 80,600 283,000
Interest and other income (expense), net 88,700 90,400 74,900 93,700 87,200 69,100 65,700 56,200 36,000 34,200 22,200 3,900 9,300 (5,700) 3,800 18,500 15,000 32,000 20,700 84,800 26,600 25,100
Income before taxes 832,100 668,500 809,800 671,000 654,500 538,500 515,900 522,000 499,200 421,800 394,700 402,800 406,900 402,400 454,200 461,100 526,200 448,800 436,500 355,200 107,200 308,100
Income tax (expense) benefit (167,900) 35,200 (121,800) (100,400) (123,000) 8,900 94,800 (102,200) (73,200) (61,000) (58,000) (78,100) (93,300) (33,000) (71,500) (73,900) (3,200) (13,600) (72,900) (38,400) (37,000) 8,100
Net income 664,200 703,700 688,000 570,600 531,500 547,400 610,700 419,800 426,000 360,800 336,700 324,700 313,600 369,400 382,700 387,200 523,000 435,200 363,600 316,800 70,200 316,200
Net income attributable to noncontrolling interest in joint venture (5,800) (5,300) (2,300) (5,500) (4,600) (2,500) (4,500) (4,100) (5,200) (5,500) (11,800) (700) (5,800) (3,800) (2,100) (6,700) (5,800) (8,900) 1,600 (2,900) (2,200) (2,700)
Net income attributable to Intuitive Surgical, Inc. 658,400 698,400 685,700 565,100 526,900 544,900 606,200 415,700 420,800 355,300 324,900 324,000 307,800 365,600 380,600 380,500 517,200 426,300 365,200 313,900 68,000 313,500

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


The financial data reveals several trends and patterns in the company’s quarterly performance over the examined periods.

Revenue Trends
Overall revenue, comprised of product and service revenues, shows a generally increasing trend from 2020 through 2025. Product revenue exhibits some volatility, with noticeable dips and recoveries, but the general trajectory is upward, peaking significantly in late 2024 and early 2025. Service revenue grows steadily over time, contributing to gradual overall revenue growth.
Cost of Revenue and Gross Profit
Cost of revenue increases consistently, reflecting higher production and service delivery costs. Product-related costs dominate this increase, growing in magnitude alongside product revenue. Despite rising costs, gross profit shows an upward trend, indicating continued operational leverage and effective cost management relative to sales growth.
Operating Expenses
Operating expenses, including selling, general and administrative (SG&A) expenses and research and development (R&D), have risen steadily. SG&A costs fluctuate but trend upwards, with some quarters showing sharp increases, suggesting higher investment in marketing or administrative functions. R&D expenses also demonstrate a gradual increase, underlining ongoing commitment to innovation and product development.
Operational Income and Profitability
Income from operations generally rises, albeit with some fluctuations correlating to revenue and expense changes. The growth in operating income reflects the company’s ability to grow sales faster than the increase in operating expenses. This operational profitability strengthens over time, with the highest figures appearing in the latest quarters.
Net Income and Tax Impact
Net income attributable to the company exhibits an upward trajectory overall, despite volatility in some quarters. Notably, net income spikes in a few periods, reflecting possibly non-recurring items or improved operational efficiency. Income tax expense fluctuates significantly, sometimes showing benefits, which impacts net income variability. The tax swings suggest complex tax planning and variability in tax liabilities.
Other Income and Expenses
Interest and other income contribute positively but with variable impact quarter to quarter. This component shows modest growth and occasionally large increases, which slightly enhance income before taxes.
Summary of Financial Health
The data indicates sustained revenue growth supported by rising product and service sales. Cost increases are managed such that profitability improves steadily. The company's investment in SG&A and R&D suggest a focus on growth and innovation. Fluctuations in tax expense introduce variability in net income but do not overshadow the overall positive performance trend. The financial trends imply a strengthening operational position with growing profitability over the analyzed period.